<?xml version='1.0' encoding='utf-8'?>
<document id="12698305"><sentence text="Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects."><entity charOffset="36-46" id="DDI-PubMed.12698305.s1.e0" text="retigabine" /><entity charOffset="51-62" id="DDI-PubMed.12698305.s1.e1" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.12698305.s1.e0" e2="DDI-PubMed.12698305.s1.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s1.e0" e2="DDI-PubMed.12698305.s1.e1" /></sentence><sentence text="The antiepileptic drugs (AEDs) retigabine (RGB) and lamotrigine (LTG) undergo predominantly N-glucuronidation and renal excretion"><entity charOffset="31-41" id="DDI-PubMed.12698305.s2.e0" text="retigabine" /><entity charOffset="43-46" id="DDI-PubMed.12698305.s2.e1" text="RGB" /><entity charOffset="52-63" id="DDI-PubMed.12698305.s2.e2" text="lamotrigine" /><entity charOffset="65-68" id="DDI-PubMed.12698305.s2.e3" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e0" e2="DDI-PubMed.12698305.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e0" e2="DDI-PubMed.12698305.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e0" e2="DDI-PubMed.12698305.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e0" e2="DDI-PubMed.12698305.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e1" e2="DDI-PubMed.12698305.s2.e1" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e1" e2="DDI-PubMed.12698305.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e1" e2="DDI-PubMed.12698305.s2.e3" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e2" e2="DDI-PubMed.12698305.s2.e2" /><pair ddi="false" e1="DDI-PubMed.12698305.s2.e2" e2="DDI-PubMed.12698305.s2.e3" /></sentence><sentence text=" This study was performed to evaluate potential pharmacokinetic interactions between both AEDs" /><sentence text="" /><sentence text="Twenty-nine healthy male subjects participated in the study" /><sentence text=" Group A ( n=14) received single oral 200-mg RGB doses on day 1 and day 7, and 25 mg o"><entity charOffset="45-47" id="DDI-PubMed.12698305.s6.e0" text="RGB" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" LTG on days 3-8"><entity charOffset="1-3" id="DDI-PubMed.12698305.s9.e0" text="LTG" /></sentence><sentence text=" Group B ( n=15) received single oral 200-mg LTG doses on day 1 and day 17, and was up-titrated to 300 mg RGB b"><entity charOffset="106-108" id="DDI-PubMed.12698305.s10.e0" text="RGB" /><entity charOffset="45-47" id="DDI-PubMed.12698305.s10.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s10.e1" e2="DDI-PubMed.12698305.s10.e1" /><pair ddi="false" e1="DDI-PubMed.12698305.s10.e1" e2="DDI-PubMed.12698305.s10.e0" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=" on days 6-20" /><sentence text=" Blood samples were collected to compare the pharmacokinetics of both AEDs and the N-acetyl metabolite of RGB (AWD21-360) after single and concomitant treatments"><entity charOffset="83-91" id="DDI-PubMed.12698305.s14.e0" text="N-acetyl" /><entity charOffset="106-113" id="DDI-PubMed.12698305.s14.e1" text="RGB" /><pair ddi="false" e1="DDI-PubMed.12698305.s14.e0" e2="DDI-PubMed.12698305.s14.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s14.e0" e2="DDI-PubMed.12698305.s14.e1" /></sentence><sentence text="" /><sentence text="RGB was rapidly absorbed and eliminated with a mean half-life (t(1/2)) of 6"><entity charOffset="0-2" id="DDI-PubMed.12698305.s16.e0" text="RGB" /></sentence><sentence text="3+/-1" /><sentence text="1 h and an apparent clearance (CL/F) of 0" /><sentence text="69+/-1" /><sentence text="4 l/h/kg" /><sentence text=" Under co-administration of LTG, mean RGB t(1/2) and area under the plasma concentration-time curve (AUC) were increased by 7"><entity charOffset="38-40" id="DDI-PubMed.12698305.s21.e0" text="RGB" /><entity charOffset="28-30" id="DDI-PubMed.12698305.s21.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s21.e1" e2="DDI-PubMed.12698305.s21.e1" /><pair ddi="false" e1="DDI-PubMed.12698305.s21.e1" e2="DDI-PubMed.12698305.s21.e0" /></sentence><sentence text="5% ( P=0" /><sentence text="045) and 15% ( P=0" /><sentence text="006), respectively, while CL/F was decreased by 13% ( P=0" /><sentence text="06)" /><sentence text=" Consistent results were obtained for AWD21-360" /><sentence text=" LTG was moderately rapidly absorbed, eliminated with a mean t(1/2) of 37+/-10"><entity charOffset="1-3" id="DDI-PubMed.12698305.s27.e0" text="LTG" /></sentence><sentence text="4 h and a CL/F of 0" /><sentence text="028+/-0" /><sentence text="007 l/h/kg" /><sentence text=" Under co-administration of RGB, mean LTG t(1/2) and AUC decreased by 15% and 18%, respectively, while CL/F increased by 22% (all parameters, P=0"><entity charOffset="28-30" id="DDI-PubMed.12698305.s31.e0" text="RGB" /><entity charOffset="38-40" id="DDI-PubMed.12698305.s31.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s31.e0" e2="DDI-PubMed.12698305.s31.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s31.e0" e2="DDI-PubMed.12698305.s31.e1" /></sentence><sentence text="001)" /><sentence text="" /><sentence text="RGB and LTG exhibit a modest pharmacokinetic interaction on each other"><entity charOffset="0-2" id="DDI-PubMed.12698305.s34.e0" text="RGB" /><entity charOffset="8-10" id="DDI-PubMed.12698305.s34.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s34.e0" e2="DDI-PubMed.12698305.s34.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s34.e0" e2="DDI-PubMed.12698305.s34.e1" /></sentence><sentence text=" The slight decline in RGB clearance due to LTG is believed to result from competition for renal elimination rather than competition for glucuronidation"><entity charOffset="23-25" id="DDI-PubMed.12698305.s35.e0" text="RGB" /><entity charOffset="44-46" id="DDI-PubMed.12698305.s35.e1" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s35.e0" e2="DDI-PubMed.12698305.s35.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s35.e0" e2="DDI-PubMed.12698305.s35.e1" /></sentence><sentence text=" The induction of LTG clearance due to retigabine was unexpected since RGB did not show enzyme induction in various other drug-drug interaction studies"><entity charOffset="39-49" id="DDI-PubMed.12698305.s36.e0" text="retigabine" /><entity charOffset="71-80" id="DDI-PubMed.12698305.s36.e1" text="RGB" /><entity charOffset="18-27" id="DDI-PubMed.12698305.s36.e2" text="LTG" /><pair ddi="false" e1="DDI-PubMed.12698305.s36.e2" e2="DDI-PubMed.12698305.s36.e2" /><pair ddi="false" e1="DDI-PubMed.12698305.s36.e2" e2="DDI-PubMed.12698305.s36.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s36.e2" e2="DDI-PubMed.12698305.s36.e1" /><pair ddi="false" e1="DDI-PubMed.12698305.s36.e0" e2="DDI-PubMed.12698305.s36.e0" /><pair ddi="false" e1="DDI-PubMed.12698305.s36.e0" e2="DDI-PubMed.12698305.s36.e1" /></sentence><sentence text=" Further studies in patients are needed to assess the clinical relevance of these findings for concomitant treatment with both drugs in the upper recommended dose range" /><sentence text="" /></document>